CN109678981B - Preparation method, product and application of safflower polysaccharide - Google Patents
Preparation method, product and application of safflower polysaccharide Download PDFInfo
- Publication number
- CN109678981B CN109678981B CN201811547397.0A CN201811547397A CN109678981B CN 109678981 B CN109678981 B CN 109678981B CN 201811547397 A CN201811547397 A CN 201811547397A CN 109678981 B CN109678981 B CN 109678981B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- safflower
- water
- extracting
- carthamus tinctorius
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000020518 Carthamus tinctorius Species 0.000 title claims abstract description 102
- 235000003255 Carthamus tinctorius Nutrition 0.000 title claims abstract description 101
- 150000004676 glycans Chemical class 0.000 title claims abstract description 101
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 101
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011347 resin Substances 0.000 claims abstract description 24
- 229920005989 resin Polymers 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- 229920005654 Sephadex Polymers 0.000 claims abstract description 13
- 239000012507 Sephadex™ Substances 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000010257 thawing Methods 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 229930003944 flavone Natural products 0.000 claims abstract description 5
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 5
- 235000011949 flavones Nutrition 0.000 claims abstract description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 6
- 230000000149 penetrating effect Effects 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000001471 micro-filtration Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000011343 solid material Substances 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 14
- 241000628997 Flos Species 0.000 abstract description 7
- 239000002244 precipitate Substances 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 239000002955 immunomodulating agent Substances 0.000 abstract description 3
- 230000002584 immunomodulator Effects 0.000 abstract description 3
- 229940121354 immunomodulator Drugs 0.000 abstract description 3
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 239000012141 concentrate Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 238000004108 freeze drying Methods 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 230000001376 precipitating effect Effects 0.000 abstract description 2
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 238000002798 spectrophotometry method Methods 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
- 229960001031 glucose Drugs 0.000 description 15
- 238000001179 sorption measurement Methods 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 11
- 150000002772 monosaccharides Chemical class 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 9
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 6
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229930182830 galactose Natural products 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 238000009777 vacuum freeze-drying Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- -1 alkaloid compounds Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013582 standard series solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical class O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Sustainable Development (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a method for preparing safflower polysaccharide, a product and application thereof, wherein the method comprises the following steps: extracting Carthami flos with hot water, settling at low temperature, filtering, removing total flavone and safflower pigment with polar macroporous resin, precipitating the crude polysaccharide concentrate with ethanol at low temperature, dissolving the precipitate with water, freeze thawing, centrifuging, purifying with Sephadex gel to obtain high-content Carthami flos polysaccharide, and freeze drying to obtain white powder. The polysaccharide content is 85.0-99.8% by ultraviolet spectrophotometry (phenol-sulfuric acid method). The invention has simple process, easy operation and high content of safflower polysaccharide, is suitable for industrial production, can be developed into medicines and health-care foods, can be used as an immunomodulator for treating immune-related diseases, and can also be used for improving the immunity of sub-health people and cancer patients receiving radiotherapy and chemotherapy.
Description
Technical Field
The invention belongs to the technical field of natural product extraction, and particularly relates to a method for preparing safflower polysaccharide, a product and application of the safflower polysaccharide.
Background
The safflower is dry tubular flower of Carthamus tinctorius L of Compositae, is pungent and warm in nature, has effects of promoting blood circulation for removing blood stasis, dredging channels and relieving pain, and has wide clinical application. The chemical components of safflower are complex, and the safflower mainly contains safflower yellow, safflower polysaccharide, flavone, organic acid, safflower red, polyphenol, amino acid and the like. "Xinhua No. 7" is a new variety of medicinal white safflower with less thorns bred by economic crops of Xinjiang academy of agricultural sciences, and the contents of the polysaccharide and the total flavone of the safflower of the variety are more than several times of those of the common safflower. Research shows that the safflower polysaccharide has pharmacological effects of oxidation resistance, immunoregulation, cancer resistance and the like, and has good inhibitory effect on S180 sarcoma cells of mice, LA795 lung cancer cells of mice, SMMC-7721 liver cancer cells of human, MC-7 breast cancer cells of human and SGC-7901 gastric cancer cells of human (see Ma Xinbo 'Chongqing medicine' at No. 43 No. 3 'research progress of extraction process of safflower polysaccharide and pharmacological effect of cancer inhibition').
At present, the method for extracting safflower polysaccharide mostly adopts a water extraction and alcohol precipitation method to obtain crude polysaccharide, and then adopts a series of methods such as Sevage method protein removal, hydrogen peroxide decoloration, acetone and ether multiple washing, drying and the like to purify to obtain the safflower polysaccharide. The purification method has the defects of complex process, large consumption of various organic reagents, mostly inflammable and explosive substances, high production cost, incapability of being suitable for industrial production and the like, and the obtained safflower polysaccharide is a multi-component mixture, is yellow brown in color, low in content and high in organic solvent residue. Therefore, at present, no medicine or health care product prepared based on high-content refined safflower polysaccharide exists.
Disclosure of Invention
In order to overcome the problems, the invention provides a method (or an extraction method) for preparing safflower polysaccharide, which is simple and reasonable, green and environment-friendly, high in continuous operation efficiency, low in production cost, uniform in component and high in content of the obtained product, rich in raw material resources and suitable for industrial production.
The invention also provides a safflower polysaccharide product prepared by the method, which has uniform components, high content and no solvent residue.
The invention also provides a medicine and a health-care product which are prepared from the safflower polysaccharide product and are used for treating immune-related diseases.
A preparation method of safflower polysaccharide comprises the following steps:
(1) soaking Carthami flos in the extractant to obtain extractive solution;
(2) adsorbing the obtained extract by macroporous resin, removing flavonoid impurities, decolorizing, and collecting the penetrating liquid;
(3) concentrating the penetrating liquid, adding alcohol into the concentrated liquid, standing for alcohol precipitation, and performing solid-liquid separation to obtain a solid material;
(4) adding water to the obtained solid material for dissolving, and carrying out freeze thawing centrifugation at low temperature;
(5) controlling the concentration of the centrifugate within the range of 200 mg/mL-600 mg/mL, and separating and purifying by using sephadex to obtain a safflower polysaccharide refined product.
In a preferred embodiment of the preparation method of the present invention, in the step (1), the extractant is water, and is further preferably ultrapure water, 0 to 50% methanol water (i.e., methanol having a concentration of 0 to 50% by volume), and 0 to 50% ethanol water. The extraction temperature is controlled to be 60-100 ℃, the extraction is carried out for 2-3 times, each time lasts for 0.5-12 hours, and the water adding amount is 10-30 times of the weight of the crude drug; after extraction, combining the extracting solutions, settling at the temperature of 2-15 ℃ for 4-24 hours to remove insoluble impurities, and then finely filtering by a liquid cross-flow membrane microfiltration system to obtain the final extracting solution.
In a preferred embodiment of the preparation method of the present invention, the macroporous resin non-polar adsorption macroporous resin (such as X-5 non-polar adsorption macroporous resin, H103 non-polar adsorption macroporous resin, HPD100 non-polar adsorption macroporous resin, etc.), medium-polar macroporous adsorption resin (such as HPD400 macroporous adsorption resin, ADS-8 macroporous adsorption resin, ADS-17 macroporous adsorption resin, etc.), polar macroporous adsorption resin. More preferred is polar macroporous adsorption resin, which refers to adsorption resin containing nitrogen, oxygen and sulfur polar functional groups such as amide groups, cyano groups and phenolic hydroxyl groups, and includes but is not limited to one or more of NKA-2 polar macroporous adsorption resin, NKA-9 polar resin, S-8 polar macroporous adsorption resin, HPD600 polar macroporous adsorption resin and the like. Or other resins suitable for separating flavone, polyphenol, anthraquinone, and alkaloid compounds (such as special resins for plant extraction of XR981, H01S, H06S, and XR920D sold by Shanghai Sener chemical engineering Co., Ltd.)
In a preferred embodiment of the preparation method of the present invention, in the step (3), the penetrating fluid is concentrated to 1/4-1/40 of the original volume; adding alcohol into the concentrated solution until the mass percent concentration of the alcohol in the system is 75-95%, and then standing and precipitating the concentrated solution for 1-18 hours at the temperature of 2-8 ℃. The solid-liquid separation can adopt the modes of normal temperature filtration, suction filtration, reduced pressure filtration and the like. In the step, the alcohol solvent in the liquid obtained by solid-liquid separation is recovered, or the alcohol solvent can be directly recovered as the alcohol solvent.
In a preferred embodiment of the preparation method of the present invention, the permeate concentration method in step (3) is nanofiltration membrane concentration, scraper concentration, Mechanical Vapor Recompression (MVR) low-temperature concentration, and more preferably, MVR low-temperature concentration. The alcohol added to the concentrate is high concentration methanol, ethanol and other alcohols, more preferably 95% ethanol or anhydrous ethanol.
In a preferred embodiment of the preparation method of the present invention, in the step (4), the freezing and thawing temperature is-30 ℃ to 0 ℃, more preferably-20 ℃, and the freezing and thawing time is 2 to 48 hours, more preferably 12 to 24 hours. The centrifugation conditions are preferably: the rotating speed is higher than 4000r/pm, and the time is more than 25 min.
In a preferred embodiment of the production method of the present invention, the concentration of the centrifugate in the step 5) is 200mg/mL to 600mg/mL, more preferably 300mg/mL to 400 mg/mL. Preferably, when separation and purification are performed with sephadex, the sample volume is 2% to 30%, more preferably 10% to 20% of the gel column volume, and the eluent is water.
In a preferred embodiment of the production method of the present invention, the Sephadex LH-20, Sephadex G25, Sephadex G50, Sephadex G75 are preferred. More preferably Sephadex LH-20 and Sephadex G50, and the ratio of the height to the diameter of the gel column is 2: 1-6: 1. The eluent is preferably ultrapure water.
Purifying with Sephadex, collecting eluate, concentrating, and vacuum freeze drying to obtain refined Carthami flos polysaccharide as white powder. The polysaccharide content is 85.0-99.8% by ultraviolet spectrophotometry (phenol-sulfuric acid method).
In the present invention, the safflower is a Compositae safflower or a new variety of white safflower, more preferably white safflower. When adopting white safflower as the raw materials, through conductance detector and ultraviolet detector monitoring, can collect 2 fraction eluents, through concentration, vacuum freeze-drying, can obtain the refined product of safflower polysaccharide of two kinds of single components: the content of safflower polysaccharide A and safflower polysaccharide B is above 90%.
A safflower polysaccharide is prepared by the preparation method of the safflower polysaccharide of any one technical proposal.
Preferably, the carthamus tinctorius polysaccharide comprises a carthamus tinctorius polysaccharide A and a carthamus tinctorius polysaccharide B, and the mass ratio of the carthamus tinctorius polysaccharide A to the carthamus tinctorius polysaccharide B is 1: 1-2; more preferably 1:1.4 to 1.6.
Preferably, the relative molecular mass of the carthamus tinctorius polysaccharide A is 8000-10000, and the relative molecular mass of the carthamus tinctorius polysaccharide B is 4000-6000. More preferably, the relative molecular mass of the carthamus tinctorius polysaccharide A is about 9400, and the relative molecular mass of the carthamus tinctorius polysaccharide B is about 5900.
Preferably, the carthamus tinctorius polysaccharide A is composed of one or more of 6 monosaccharides of rhamnose, arabinose, glucose, galactose, xylose and mannose; more preferably, the safflower polysaccharide A is formed by connecting 6 monosaccharides such as rhamnose, arabinose, glucose, galactose, xylose and mannose by a beta-chain; preferably, the carthamus tinctorius polysaccharide B consists of one or more of 4 monosaccharides of arabinose, glucose, galactose and rhamnose; more preferably, the carthamus tinctorius polysaccharide B is formed by connecting 4 monosaccharides of arabinose, glucose, galactose and rhamnose in a beta-chain manner.
A pharmaceutical and health product for treating immune-related diseases, comprising the carthamus tinctorius polysaccharide and its composition of claim 1 in an amount effective for treating or preventing immune-related diseases, and a pharmaceutically acceptable carrier. Such pharmaceutically acceptable carriers include, but are not limited to, adjuvants, shaping agents, flavoring agents, and the like.
The medicine and health product for treating immune related diseases can be prepared into oral preparations and injection preparations.
The safflower polysaccharide prepared by the invention has the following functions:
the in vitro leaching experiment shows that the carthamus tinctorius polysaccharide and T cell mitogen ConA have synergistic effect and have no obvious influence on B cell mitogen. However, in vivo PFC tests, the action trend of carthamus tinctorius polysaccharide is consistent with that of astragalus polysaccharide which is generally considered to act on B cells. The mice were injected with carthamus tinctorius polysaccharides at different times, and the PFC values of the mice varied: the PFC in the post-sensitization group was promoted, while the PFC reaction in the pre-sensitization group was suppressed. The safflower polysaccharide shows the bidirectional property of the immune drug. The carthamus tinctorius polysaccharide can obviously resist the immunosuppressive action of prednisolone, and has more obvious effect on enhancing the immunity of prednisolone-inhibiting mice than normal mice. Therefore, the carthamus tinctorius polysaccharide can promote lymphocyte transformation, increase the number of cells formed by splenocytes to sheep red blood cell plaques, and resist the immunosuppressive effect of prednisolone. The polysaccharides component of Carthami flos can induce interferon generation via lFN-lL-NKC network, and regulate cytokine network, T cell network, and endocrine immune network, thereby enhancing immunity. Therefore, the safflower polysaccharide can be used as an immunomodulator for treating immune-related diseases.
The invention has the following beneficial effects:
the invention has simple process, easy operation and high content of safflower polysaccharide, is suitable for industrial production, can be developed into medicines and health-care foods, can be used as an immunomodulator for treating immune-related diseases, and can also be used for improving the immunity of sub-health people and cancer patients receiving radiotherapy and chemotherapy.
The invention can adopt a new medicinal white safflower variety 'New safflower No. 7' as a raw material, the variety has rich resources, and the content of safflower polysaccharide is more than several times of that of common safflower, thereby ensuring the purity and the overall yield of the final product from the source.
The preparation method provided by the invention adopts high-efficiency separation and purification methods such as large-scale membrane microfiltration, macroporous resin specific adsorption and directional separation, sephadex refining and the like, the content of the obtained safflower polysaccharide is 85.0-99.8%, the curative effect of the product is ensured, the reproducibility is good, the defects of low extraction rate, poor reproducibility and the like of the safflower polysaccharide in the prior art are overcome, and importantly, the preparation method is convenient to carry and take and has activity superior to that of a safflower water decoction.
The invention adopts the preparation processes of low-energy MVR low-temperature concentration, alcohol precipitation freeze thawing, freeze drying and the like, avoids the structure change and loss of active ingredients and the reduction of physiological activity caused by high-temperature conditions in the prior art, and the obtained product has stable quality and is easy for large-scale production.
Detailed Description
In order to make the objects and advantages of the present invention more apparent, the present invention is further described with reference to the following examples. It should be understood that the specific embodiments described herein are merely illustrative of the invention and do not limit the scope of the invention.
The content of safflower polysaccharide is measured by phenol-sulfuric acid method, which comprises hydrolyzing polysaccharide under the action of sulfuric acid to obtain monosaccharide, rapidly dehydrating to obtain furfural derivative, and reacting with phenol to obtain orange yellow compound.
a) Preparation of glucose standard solution:
preparation of glucose standard solution: 10.71mg of anhydrous glucose dried to constant weight at 105 ℃ is precisely weighed, placed in a 100mL measuring flask, and fixed to the scale by distilled water to prepare stock solution of 107.1 mu g/mL. Precisely sucking 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0mL of glucose solution from the stock solution, respectively adding into 20mL test tubes with stoppers, respectively adding distilled water to 2.0mL, and preparing into glucose standard series solution. 2.0mL of distilled water was taken as a blank for zeroing.
b) Drawing of standard curve
Adding 1.0mL of 5% phenol solution into glucose standard series solution and distilled water, mixing, rapidly adding 5.0mL concentrated sulfuric acid along the tube wall, shaking, sealing, heating in boiling water bath for 15min, rapidly cooling to room temperature in ice water bath, measuring absorbance at maximum absorption wavelength of 490nm, drawing standard curve with absorbance (A) as ordinate and glucose standard solution mass concentration (C, μ g/mL) as abscissa to obtain regression equation with y of 0.0134x-0.0113, R2＝0.9992。
c) Determination of polysaccharide content in a sample
Accurately weighing 10mg of refined polysaccharide, fixing the volume in a 10mL measuring flask, and shaking up to obtain a sample solution. Then 2.0mL of the solution was aspirated and the volume was adjusted to 20 mL. Sucking 1.0mL of sample liquid to be detected, supplementing distilled water to 2mL, detecting the absorbance value according to a method for preparing a standard curve, and substituting into a regression equation to obtain the glucose mass concentration (mu g/mL). Calculating the mass fraction of polysaccharide according to the following formula:
polysaccharide mass fraction%
Example 1:
taking 500g of white safflower, adding 10 times of water by weight, soaking for 2h at 60 ℃ under stirring, filtering, adding 8 times of water by weight into dregs of a decoction, soaking for 1h at 60 ℃ under stirring, filtering out dregs of a decoction, and mixing about 8.1L of extracting solution. Settling the extract at 5 ℃ for 6h, and filtering the supernatant by a liquid cross-flow membrane microfiltration system. The filtrate was passed through a polar macroporous adsorbent resin (column volume 1200mL) (XR920D Shanghai Senel chemical technology Co., Ltd.) to collect a permeate of safflower polysaccharide (about 8.6L) (eluent water). Concentrating the filtrate (MVR low temperature concentration) to about 300mL, adding 3000mL 95% ethanol under stirring, sealing and standing at 4 deg.C for 12 hr, vacuum filtering to obtain 88.2g Carthami flos polysaccharide precipitate, and recovering ethanol from the filtrate. Dissolving the polysaccharide precipitate with 220mL of water, freezing and thawing at-20 deg.C for 12 hr, and centrifuging to remove protein (rotating speed of 4500r/pm for 30 min). Controlling the concentration of the centrifugate to be about 400mg/mL, purifying by Sephadex LH-20 Sephadex (the sample volume accounts for 10% of the volume of the gel column), the height-diameter ratio of the gel column is 4:1, eluting the carthamus tinctorius polysaccharide component by using water as a solvent, collecting 2 different fraction eluents (detecting by a conductivity detector and an ultraviolet detector, respectively collecting two carthamus tinctorius polysaccharides with different components), concentrating, and carrying out vacuum freeze drying to respectively obtain refined carthamus tinctorius polysaccharide A12.1g and carthamus tinctorius polysaccharide B18.0 g, wherein the total yield is 6.02%. The contents were 93.60% and 92.75% respectively, as determined spectrophotometrically.
Example 2:
taking 500g of white safflower, adding 12 times of water by weight, soaking for 2h at 100 ℃ under stirring, filtering, adding 10 times of water by weight into dregs of a decoction, soaking for 1h at 100 ℃ under stirring, filtering out dregs of a decoction, and mixing about 10.5L of extracting solution. Settling the extract at 5 ℃ for 6h, and filtering the supernatant by a liquid cross-flow membrane microfiltration system. The filtrate was passed through a polar macroporous adsorbent resin (column volume 1200mL) (XR920D Shanghai Sener chemical engineering Co., Ltd.) (eluent water) to collect about 11L of the safflower polysaccharide permeate. Concentrating the filtrate (MVR low temperature concentration) to about 400mL, adding 4000mL of 95% ethanol under stirring, sealing and standing at 4 deg.C for 16h, vacuum filtering to obtain 96.5g of Carthami flos polysaccharide precipitate, and recovering ethanol from the filtrate. Dissolving the polysaccharide precipitate with 300mL of water, freezing and thawing at-10 deg.C for 24 hr, and centrifuging to remove protein (rotation speed of 5000r/pm for 30 min). Controlling the concentration of the centrifugate to be about 300mg/mL, purifying by Sephadex LH-20 Sephadex (the sample volume accounts for 20% of the volume of the gel column), the height-diameter ratio of the gel column is 5:1, eluting the carthamus tinctorius polysaccharide component by using water as a solvent, collecting 2 different fraction eluents (detecting by a conductivity detector and an ultraviolet detector, respectively collecting two different components of carthamus tinctorius polysaccharide), concentrating, and carrying out vacuum freeze drying to respectively obtain refined carthamus tinctorius polysaccharide A13.5g and carthamus tinctorius polysaccharide B20.3 g, wherein the total yield is 6.76%. The contents were 91.92% and 91.39%, respectively, as determined spectrophotometrically.
And (3) carrying out structure detection on the carthamus tinctorius polysaccharide A and the carthamus tinctorius polysaccharide B:
gel permeation chromatography (size exclusion chromatography) method to determine its relative molecular mass:
1. chromatographic condition chromatographic column TSK-GELG4000PWXLColumns (300 mm. times.7.8 mm, 10 μm); mobile phase: ultrapure water; the column temperature is 30 ℃; a detector: a differential Refractometer (RID) with a detector temperature of 30 ℃; flow rate of 0.5 mL/min-1(ii) a Sample introduction volume: 10 μ L.
2. Preparation of a standard curve dextran reference substances with known relative molecular mass (relative molecular weight is 2000-50000) are respectively added with ultrapure water to prepare solutions containing 1mg per 1mL, and the solutions are filtered through a 0.45 mu m microporous filter membrane to obtain the dextran. A standard curve was prepared with the log of the Molecular Weight (MW) of the control and its corresponding retention time (tR).
3. Determination of sample molecular weight safflower polysaccharide is prepared into 1 mg/mL by distilled water-1The solution is filtered through a 0.45 mu m microporous filter membrane, sample injection analysis is carried out under the chromatographic condition, retention time is recorded, and the retention time is substituted into a regression equation to calculate the relative molecular mass of each component. As a result, the relative molecular mass of the carthamus tinctorius polysaccharide A was 9400 or so, and the relative molecular mass of the carthamus tinctorius polysaccharide B was 5900 or so.
And (3) analyzing the monosaccharide composition and the structure by using a derivatization gas chromatography:
1. chromatographic conditions chromatographic column: HP-5(30 m.times.0.32 mm); temperature programming:
100℃(5℃·min-1)→190℃(4℃·min-1) → 240 deg.C (5 min); carrier gas: high purity nitrogen gas(ii) a Sample injector temperature: 260 ℃; and (3) sample introduction mode: shunting; the detector is FID; the injection port temperature is 250 ℃.
2. Preparation of monosaccharide reference substance and glyconitrile acetate derivative of hydrolyzed polysaccharide accurately weighing 6 standard monosaccharides of L-rhamnose, L-arabinose, D-xylose, D-mannose, D-glucose and D-galactose and 10mg of 2 hydrolyzed polysaccharide samples, respectively placing into a test tube with a plug, adding 10mg of hydroxylamine hydrochloride and 7mg of internal standard, adding anhydrous pyridine lmL, placing into a water bath at 90 ℃ for heating for 30min and oscillating, taking out, cooling to room temperature, adding anhydrous acetic anhydride lmL, continuing to react at 90 ℃ for 30min for acetylation, extracting chloroform, and injecting samples.
The result shows that the safflower polysaccharide A is formed by connecting 6 monosaccharides of rhamnose, arabinose, glucose, galactose, xylose and mannose by a beta-chain; the safflower polysaccharide B is formed by connecting 4 monosaccharides of arabinose, glucose, galactose and rhamnose by beta-chains.
Claims (5)
1. The preparation method of the safflower polysaccharide is characterized by comprising the following steps:
(1) placing new safflower No. 7 in an extracting agent, and soaking and extracting to obtain an extracting solution;
(2) adsorbing the obtained extractive solution with polar macroporous adsorbent resin XR920D, removing flavone impurities, decolorizing, and collecting penetrating liquid;
(3) concentrating the penetrating fluid at low temperature by adopting MVR, and concentrating the penetrating fluid to 1/4-1/40 of the original volume; adding alcohol into the concentrated solution until the mass percentage concentration of the alcohol in the system is 75-95%, standing at 2-8 ℃ for alcohol precipitation for 1-18 hours, and performing solid-liquid separation to obtain a solid material;
(4) adding water into the obtained solid material for dissolving, and performing freeze thawing centrifugation at low temperature, wherein the freeze thawing temperature is-30-0 ℃, and the freeze thawing time is 2-48 hours;
(5) controlling the concentration of the centrifugate within the range of 200 mg/mL-600 mg/mL, and separating and purifying by using sephadex to obtain a safflower polysaccharide refined product; the Sephadex LH-20 is Sephadex LH-20;
in the step (1), the extracting agent is water, 0-50% of methanol water and 0-50% of ethanol water, the extracting temperature is controlled to be 60-100 ℃, the extracting is carried out for 2-3 times, each time lasts for 0.5-12 hours, and the water adding amount is 10-30 times of the weight of the crude drug; after extraction is finished, combining the extracting solutions, settling for 4-24 hours at the temperature of 2-15 ℃ to remove insoluble impurities, and then performing fine filtration by a liquid cross-flow membrane microfiltration system to obtain a final extracting solution;
when the sephadex is used for separation and purification, the sample loading volume accounts for 2-30% of the volume of the gel column, and the eluent is water;
the safflower polysaccharide refined product comprises safflower polysaccharide A and safflower polysaccharide B, and the mass ratio of the safflower polysaccharide A to the safflower polysaccharide B is 1: 1-2; the relative molecular mass of the carthamus tinctorius polysaccharide A is 8000-10000, and the relative molecular mass of the carthamus tinctorius polysaccharide B is 4000-6000.
2. The method for producing carthamus tinctorius polysaccharide according to claim 1, wherein in the step (4), the centrifugation conditions are as follows: the rotating speed is higher than 4000r/pm, and the time is more than 25 min.
3. The method for preparing carthamus tinctorius polysaccharide according to claim 1, wherein the ratio of the height to the diameter of the gel column is 2: 1-6: 1.
4. A safflower polysaccharide which is produced by the method for producing a safflower polysaccharide according to any one of claims 1 to 3.
5. A medicine and health product for treating immune-related diseases, which is characterized by comprising the safflower polysaccharide and the composition thereof as claimed in claim 4 in an amount effective for treating or preventing the immune-related diseases and a pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811547397.0A CN109678981B (en) | 2018-12-18 | 2018-12-18 | Preparation method, product and application of safflower polysaccharide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811547397.0A CN109678981B (en) | 2018-12-18 | 2018-12-18 | Preparation method, product and application of safflower polysaccharide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109678981A CN109678981A (en) | 2019-04-26 |
| CN109678981B true CN109678981B (en) | 2021-06-01 |
Family
ID=66187903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811547397.0A Active CN109678981B (en) | 2018-12-18 | 2018-12-18 | Preparation method, product and application of safflower polysaccharide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109678981B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115120529B (en) * | 2022-06-17 | 2023-10-24 | 山东农业大学 | Red sage root and safflower compound polysaccharide, and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53126089A (en) * | 1977-04-11 | 1978-11-02 | Akiyama Jiyouzai Kk | Cyclodextrin clathrate compound including safflower oil |
| CN107189081A (en) * | 2017-06-07 | 2017-09-22 | 兰州理工大学 | A kind of Preparation method and use of multi-functional polysaccharide hydrogel |
-
2018
- 2018-12-18 CN CN201811547397.0A patent/CN109678981B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109678981A (en) | 2019-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110551230B (en) | Preparation method of astragalus polysaccharide | |
| CN110128562B (en) | An antitumor fructus Psoraleae polysaccharide, its extraction and separation method, and its application in preparing antitumor drugs | |
| CN112321656B (en) | Method for separating and preparing acylated anthocyanin | |
| CN110540603B (en) | Rhizoma anemarrhenae polysaccharide, and preparation method, identification method and application thereof | |
| CN109678981B (en) | Preparation method, product and application of safflower polysaccharide | |
| CN101709093B (en) | Method for preparing blumea riparia water-soluble polysaccharides | |
| CN112175028B (en) | Method for separating and preparing delphinidin-3-O- (6-O-p-coumaroyl) glucoside | |
| CN101322693B (en) | Carthamus tinctorius yellow colour injection and preparation technique thereof | |
| CN107652369A (en) | A kind of anticoagulation Ligustrum japonicum Thunb.flower polysaccharide and its purification methods and uses | |
| CN108409806B (en) | Method for separating and preparing petunidin-3-O-glucoside | |
| CN113121716B (en) | Cercis chinensis polysaccharide capable of promoting coagulation and extraction and separation method and application thereof | |
| CN114957497A (en) | Gentiana rigescens acidic polysaccharide and preparation method and application thereof | |
| CN107540756A (en) | One kind promotees blood coagulation Ligustrum japonicum Thunb.flower polysaccharide and its purification methods and uses | |
| CN106916065A (en) | The method that high-purity chlorogenic acid is prepared from radix bardanae | |
| CN113717296A (en) | Eucommia acidic polysaccharide, extraction method and application of eucommia acidic polysaccharide in preparation of anti-colon cancer drugs | |
| CN108948223B (en) | Myrtle polysaccharide P1, its separation method and application in preparing hypolipidemic medicine | |
| CN108516999B (en) | method for separating and preparing petunidin-3-O-galactoside | |
| CN102617727B (en) | Thymalfasin compound and novel preparation method thereof | |
| CN116731217B (en) | Ampelopsis grossedentata acidic polysaccharide AGP-2a, preparation method thereof and application thereof in preparing anti-inflammatory cosmetics | |
| CN112300233B (en) | Method for separating and preparing paeoniflorin-3-O- (6-O-p-coumaroyl) glucoside-5-glucoside | |
| CN112321655B (en) | Method for separating and preparing petunidin-3-O- (6-O-p-coumaroyl) glucoside | |
| CN116655820B (en) | Ampelopsis grossedentata acidic polysaccharide AGP-3a, extraction and separation method thereof and application thereof in preparation of anti-inflammatory cosmetics | |
| CN113234110B (en) | Method for preparing lobetyolin, atractyloide III and syringin from radix codonopsis based on PRE-HPLC | |
| CN109180485A (en) | A kind of method of separating chlorogenic acid | |
| CN115124628B (en) | Bletilla striata polysaccharide, preparation method and application thereof, and immunologic adjuvant and nano vaccine containing bletilla striata polysaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method, product and application of safflower polysaccharide Effective date of registration: 20210914 Granted publication date: 20210601 Pledgee: Industrial Commercial Bank of China Ltd. Taizhou Huangyan branch Pledgor: ZHEJIANG YONGNING PHARMACEUTICAL Co.,Ltd. Registration number: Y2021330001585 |